Andrew Cooper Analyst Performance

Vice President Life Science Tools & Services, Diagnostics & Clinical Laboratories at Raymond James Financial

Andrew Cooper is a stock analyst at Raymond James Financial focused in the medical sector, covering 14 publicly traded companies. Over the past year, Andrew Cooper has issued 24 stock ratings, including buy and hold recommendations. While full access to Andrew Cooper's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Andrew Cooper's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ranking: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 32 Last 5 Years
Buy Recommendations: 93.75% 30 Buy Ratings
Companies Covered: 14 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	9.4%	3 ratings
Buy	84.4%	27 ratings
Hold	6.3%	2 ratings
Sell	0.0%	0 ratings

Out of 32 total stock ratings issued by Andrew Cooper at Raymond James Financial, the majority (84.4%) have been Buy recommendations, followed by 9.4% Strong Buy and 6.3% Hold.

Best & Worst Calls

Best Call
0000.0%
CDNA
Aug 2020
Subscribe to MarketBeat All Access to get analyst recommendation ROI.
Worst Call
000.0%
BIOR
Aug 2020
Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	57.1% of companies on NASDAQ	8 companies
NYSE	42.9% of companies on NYSE	6 companies

Andrew Cooper, an analyst at Raymond James Financial, currently covers 14 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 13 companies	92.9%
	Industrials 1 company	7.1%

Andrew Cooper of Raymond James Financial specializes in stock coverage within the Medical sector, with additional focus on Industrials companies.

Coverage Industries

Industry	Percentage
MEDICAL SERVICES 4 companies	28.6%
MED INSTRUMENTS 3 companies	21.4%
MEDICAL INFO SYS 2 companies	14.3%
MED - BIOMED/GENE 2 companies	14.3%
MED PRODUCTS 1 company	7.1%
CONTNRS - PPR/PLS 1 company	7.1%
PHARMACEUTICAL PREPARATIONS 1 company	7.1%

About Andrew Cooper

Andrew Cooper joined Raymond James in June 2013 and the equity research team in June 2014 in the healthcare space. In February 2020 he assumed lead coverage of the diagnostics & clinical laboratories sector, with further expansion into the life science tools industry thereafter. Cooper graduated from the University of North Carolina at Chapel Hill with a bachelor of science in business administration and political science in May of 2013.

Follow on LinkedIn

Timeframe

Start Date

End Date

Rating

12-Month ROIAll ROI

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
HAE Haemonetics	8/11/2025	Downgrade	$53.88	$78.00	Outperform
AZTA Azenta	8/6/2025	Upgrade	$26.90	$35.00	Outperform
AVTR Avantor	8/4/2025	Set Price Target	$11.30	$14.00	Outperform
GH Guardant Health	7/31/2025	Boost Price Target	$41.34	$61.00	Outperform
RVTY Revvity	7/29/2025	Reiterated Rating	$95.66	$115.00	Outperform
ITGR Integer	7/25/2025	Lower Price Target	$106.48	$143.00	Outperform
TMO Thermo Fisher Scientific	7/24/2025	Reiterated Rating	$479.45	$535.00	Outperform
MYGN Myriad Genetics	5/7/2025	Reiterated Rating	$4.79	$10.00	Outperform
FLGT Fulgent Genetics	5/5/2025	Reiterated Rating	$20.04	$25.00	Outperform
HOLX Hologic	5/2/2025	Reiterated Rating	$53.21	$71.00	Outperform
RVTY Revvity	4/29/2025	Reiterated Rating	$94.90	$120.00	Outperform
ITGR Integer	4/25/2025	Boost Price Target	$121.61	$150.00	Outperform
ITGR Integer	3/28/2025	Initiated Coverage	$117.74	$145.00	Outperform
UFPT UFP Technologies	3/28/2025	Initiated Coverage	$203.23		Market Perform
MYGN Myriad Genetics	2/25/2025	Reiterated Rating	$11.68	$19.00	Outperform
GH Guardant Health	2/21/2025	Reiterated Rating	$44.43	$59.00	Outperform
AVTR Avantor	2/10/2025	Reiterated Rating	$18.93	$24.00	Outperform
HOLX Hologic	2/6/2025	Reiterated Rating	$66.04	$90.00	Outperform
DHR Danaher	2/3/2025	Reiterated Rating	$222.56		Market Perform
TMO Thermo Fisher Scientific	2/3/2025	Reiterated Rating	$598.40	$667.00	Outperform
RVTY Revvity	2/3/2025	Reiterated Rating	$126.13	$145.00	Outperform
RVTY Revvity	1/21/2025	Lower Price Target	$123.18	$140.00	Outperform
DHR Danaher	1/21/2025	Lower Price Target	$244.34	$275.00	Outperform
AVTR Avantor	1/21/2025	Lower Price Target	$22.17	$26.00	Outperform

Stock Forecasts and Research Tools

Today's Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.